Pharmacoeconomic Evaluation of Four Short－ term Triple Therapeutic Schemes for Eradicating Hp
- VernacularTitle:4组短程三联方案根除幽门螺杆菌的药物经济学评价
- Author:
Huafeng CHENG
;
Huiming CAO
;
Qian CHEN
;
Nansen ZHANG
- Publication Type:Journal Article
- From:
China Pharmacy
2001;12(3):154-155
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE： Four different one－ week triple therapeutic schemes to eradicate Helicobacter pylori were compared by pharmacoeconomic analysis to provide a scientific method for rational assignment of our limited medical fund.METHODS： According to literature reports,892 cases of duodenal ulcer and gastritis with Helicobacter pylori were selected.These patients were randomly divided into four groups which received different one－ week triple therapeutic schemes： OMC(Omeprazole＋ Metronidazole＋ Clarithromycin),OFC(Omeprazole＋ Furazolidone＋ Clarithromycin),OFA(Omeprazole＋ Furazolidone＋ Amoxicillin)and BFC(Colloidal bismuth subcitrate＋ Furazolidone＋ Clarithromycin).The schemes were evaluated with pharmacoeconomic cost－ effectiveness analysis.RESULTS： The cost－ effectiveness ratios of OMC,OFC,OFA,BFC for gastritis or duodenal ulcer were 16.19/17.33,17.30/13.93,11.40/10.56,11.17/10.75 respectively.They changed to 16.36/17.51,17.49/14.08,8.15/7.55,11.66/11.20 by sensitivity analysis.CONCLUSION： OFA is the most effective and inexpensive one to eradicate Hp.
